GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Acerus Pharmaceuticals Corp (TSX:ASP) » Definitions » Gross Margin %

Acerus Pharmaceuticals (TSX:ASP) Gross Margin % : 73.81% (As of Sep. 2022)


View and export this data going back to 2009. Start your Free Trial

What is Acerus Pharmaceuticals Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Acerus Pharmaceuticals's Gross Profit for the three months ended in Sep. 2022 was C$0.76 Mil. Acerus Pharmaceuticals's Revenue for the three months ended in Sep. 2022 was C$1.03 Mil. Therefore, Acerus Pharmaceuticals's Gross Margin % for the quarter that ended in Sep. 2022 was 73.81%.


The historical rank and industry rank for Acerus Pharmaceuticals's Gross Margin % or its related term are showing as below:


TSX:ASP's Gross Margin % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 47.01
* Ranked among companies with meaningful Gross Margin % only.

Acerus Pharmaceuticals had a gross margin of 73.81% for the quarter that ended in Sep. 2022 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Acerus Pharmaceuticals was 0.00% per year.


Acerus Pharmaceuticals Gross Margin % Historical Data

The historical data trend for Acerus Pharmaceuticals's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acerus Pharmaceuticals Gross Margin % Chart

Acerus Pharmaceuticals Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 50.07 -39.95 41.64 -85.61 127.05

Acerus Pharmaceuticals Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16.67 46.77 67.88 35.70 73.81

Competitive Comparison of Acerus Pharmaceuticals's Gross Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Acerus Pharmaceuticals's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Acerus Pharmaceuticals's Gross Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Acerus Pharmaceuticals's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Acerus Pharmaceuticals's Gross Margin % falls into.



Acerus Pharmaceuticals Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Acerus Pharmaceuticals's Gross Margin for the fiscal year that ended in Dec. 2021 is calculated as

Gross Margin % (A: Dec. 2021 )=Gross Profit (A: Dec. 2021 ) / Revenue (A: Dec. 2021 )
=-6.7 / -5.29
=(Revenue - Cost of Goods Sold) / Revenue
=(-5.29 - 1.431) / -5.29
=127.05 %

Acerus Pharmaceuticals's Gross Margin for the quarter that ended in Sep. 2022 is calculated as


Gross Margin % (Q: Sep. 2022 )=Gross Profit (Q: Sep. 2022 ) / Revenue (Q: Sep. 2022 )
=0.8 / 1.027
=(Revenue - Cost of Goods Sold) / Revenue
=(1.027 - 0.269) / 1.027
=73.81 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Acerus Pharmaceuticals  (TSX:ASP) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Acerus Pharmaceuticals had a gross margin of 73.81% for the quarter that ended in Sep. 2022 => Durable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Acerus Pharmaceuticals Gross Margin % Related Terms

Thank you for viewing the detailed overview of Acerus Pharmaceuticals's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Acerus Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
7025 Langer Drive, Suite 205, Mississauga, ON, CAN, L5N 0E8
Acerus Pharmaceuticals Corp is a specialty pharmaceutical company focused on the development, manufacture, marketing and distribution of branded products that improve patient experience, with a primary focus on the field of men's health. Its foundational product includes NATESTO, a testosterone therapy based on nasal gel technology. The company commercializes its products via its salesforce in the United States and Canada, and through a global network of licensed distributors in other territories.
Executives
Norma Beauchamp Director
Stephen Robert Gregory Director
Edward Joseph Gudaitis Director, Senior Officer

Acerus Pharmaceuticals Headlines